DAVID PAULSON: Open Payments
NPI 1740252196 · OREM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$208 in 10 payments from 8 companies in 2025. Trend: 2023 $185 · 2024 $297 · 2025 $208
Food & beverage: $208
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Alkermes, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| ABBVIE INC. | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
Products named: CAPLYTA, Qelbree, LYBALVI, REXULTI, TRINTELLIX, COBENFY, VRAYLAR, Dyanavel XR.
Industry payments across UT — which companies pay providers there.
